S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Forecast, Price & News

$80.01
+0.67 (+0.84%)
(As of 05:11 PM ET)
Compare
Today's Range
$77.10
$80.35
50-Day Range
$66.23
$88.73
52-Week Range
$24.01
$90.15
Volume
1.28 million shs
Average Volume
540,144 shs
Market Capitalization
$2.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.29

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
8.8% Downside
$72.29 Price Target
Short Interest
Bearish
10.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of TransMedics Group in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.56 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.62) to ($0.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

949th out of 981 stocks

Electromedical Equipment Industry

21st out of 22 stocks


TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
TransMedics: Expensive, But High Potential
TransMedics Group (NASDAQ:TMDX) Sees Large Volume Increase
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
TransMedics Group (NASDAQ:TMDX) Shares Gap Down to $74.02
Is TransMedics Group Stock a Buy on the Dip?
Q1 2023 Transmedics Group Inc Earnings Call
TransMedics Reports First Quarter 2023 Financial Results
See More Headlines

TMDX Price History

TMDX Company Calendar

Last Earnings
5/01/2023
Today
6/08/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$72.29
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
-9.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-36,230,000.00
Pretax Margin
-23.70%

Debt

Sales & Book Value

Annual Sales
$93.46 million
Book Value
$5.87 per share

Miscellaneous

Free Float
30,373,000
Market Cap
$2.60 billion
Optionable
Not Optionable
Beta
1.45

Key Executives

  • Waleed H. HassaneinWaleed H. Hassanein
    President, Chief Executive Officer & Director
  • John F. CareyJohn F. Carey
    Vice President-Operations
  • Stephen GordonStephen Gordon
    Chief Financial Officer, Secretary & Treasurer
  • Mark Anderson
    Senior Director-Technology Development
  • Phillip Camp
    Chief Medical Officer













TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2023?

7 equities research analysts have issued 1 year target prices for TransMedics Group's stock. Their TMDX share price forecasts range from $45.00 to $90.00. On average, they expect the company's share price to reach $72.29 in the next twelve months. This suggests that the stock has a possible downside of 9.7%.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2023?

TransMedics Group's stock was trading at $61.72 at the start of the year. Since then, TMDX stock has increased by 29.6% and is now trading at $80.01.
View the best growth stocks for 2023 here
.

Are investors shorting TransMedics Group?

TransMedics Group saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,300,000 shares, an increase of 35.2% from the April 30th total of 2,440,000 shares. Based on an average daily volume of 635,600 shares, the short-interest ratio is currently 5.2 days.
View TransMedics Group's Short Interest
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings data on Monday, May, 1st. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.17. The company had revenue of $41.60 million for the quarter, compared to the consensus estimate of $36.05 million. TransMedics Group had a negative net margin of 23.76% and a negative trailing twelve-month return on equity of 18.30%. The firm's revenue was up 161.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.38) EPS.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.00 million-$170.00 million, compared to the consensus revenue estimate of $157.66 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (10.00%), BlackRock Inc. (6.93%), Macquarie Group Ltd. (5.36%), Fred Alger Management LLC (3.51%), Allspring Global Investments Holdings LLC (2.94%) and Credit Suisse AG (2.53%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $80.01.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.60 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does TransMedics Group have?

The company employs 148 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -